Publication
Number of items: 10.
Restricted
MINOCA presenting with STEMI – incidence, aetiology and outcome in a contemporaneous cohort. (2019)
Ying X. Gue,
Natasha Corballis,
Alisdair Ryding,
Juan Carlos Kaski
and
Diana Gorog
![]()
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome. (2019)
Ying X Gue,
Rahim Kanji,
David M Wellsted,
Manivannan Srinivasan,
Solange Wyatt
and
Diana A Gorog
![]()
Incidence of thrombotic complications in COVID-19. (2021)
William Jenner
and
Diana Gorog
![]()
Thrombotic complications in 2,928 patients with COVID-19 treated in intensive care: a systematic review. (2021)
William Jenner,
Rahim Kanji,
Saeed Mirsadraee,
Ying X. Gue,
Susanna Price,
Sanjay Prasad
and
Diana Gorog
![]()
PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. (2014)
G. Rosser,
P. Tricoci,
D. Morrow,
C. Christopoulos,
M. Niespialowska-Steuden,
Robert Kozarski,
R. Wilcox
and
Diana Gorog
![]()
Impaired endogenous fibrinolysis at high shear using a point-of-care test in STEMI is associated with alterations in clot architecture. (2019)
Nikolaos Spinthakis,
Ying Gue,
Mohamed Farag,
Guogang Ren,
Manivannan Srinivasan,
Anwar Baydoun
and
Diana A Gorog
![]()